Compare BAER & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BAER | PEPG |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | 235 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.0M | 121.7M |
| IPO Year | N/A | 2022 |
| Metric | BAER | PEPG |
|---|---|---|
| Price | $1.92 | $1.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $5.00 | ★ $11.17 |
| AVG Volume (30 Days) | 345.3K | ★ 1.1M |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.61 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.47 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.47 | $1.01 |
| 52 Week High | $3.44 | $7.80 |
| Indicator | BAER | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 49.18 | 38.93 |
| Support Level | $1.58 | $1.47 |
| Resistance Level | $1.93 | $1.96 |
| Average True Range (ATR) | 0.12 | 0.22 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 51.71 | 1.09 |
Bridger Aerospace Group Holdings Inc operates as an aerial firefighting company. It provides aerial wildfire surveillance, relief and suppression, and aerial firefighting services using next-generation technology and environmentally friendly and sustainable firefighting methods. Its revenues is derived from aerial wildfire management, relief and suppression and the delivery of specialty aviation services. The company's portfolio is organized across three offerings namely : Fire Suppression; Aerial Surveillance; and Maintenance, Repair and Overhaul (MRO). The company operates as a single operating segment. Its revenues are derived from aerial wildfire management, relief and suppression and the delivery of specialty aviation service. Geographically, it operates in Spain and United States.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.